Latest CancerVax Stories
SAN DIEGO, April 11, 2011 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP).
There could soon new treatment for one of the most deadly forms of cancer, thanks to a study from the University of East Anglia and Children's Hospital Boston.
A new drug shown to help prolong the lives of people suffering from advanced skin cancer has been approved by the FDA.
CAMBRIDGE, Mass., Feb.
CAMBRIDGE, Mass., Dec.
CAMBRIDGE, Mass. and NEW YORK, Dec.
DALLAS, September 28, 2010 /PRNewswire/ -- ReportsandReports announces it will carry Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Research Report in its store. Browse the complete Report on: http://www.reportsandreports.com/reports/33665-emerging-cancer-vaccines- forecasts-developments-and-pipeline-an.html Search More Than 50000 Market Research Reports at ReportsandReports (http://www.reportsandreports.com/) Browse All Kalorama...
NESS ZIONA, Israel, September 20, 2010 /PRNewswire-FirstCall/ -- NasVax (TASE: NSVX) announces that it has initiated recruitment and dosing in a Phase 2a clinical trial for oral anti-CD3 (aCD3) monoclonal antibody (MAb) immunotherapy.
SAN DIEGO, Aug.
SAN DIEGO, Aug.
- An armed gangster.